Hepatocellular carcinoma(HCC) is the fifth most common form of human cancer worldwide and the third most common cause of cancer-related deaths. The strategies of various treatments for HCC depend on the stage of tumor...Hepatocellular carcinoma(HCC) is the fifth most common form of human cancer worldwide and the third most common cause of cancer-related deaths. The strategies of various treatments for HCC depend on the stage of tumor,the status of patient's performance and the reserved hepatic function. The Barcelona Clinic Liver Cancer(BCLC) staging system is currently used most for patients with HCC. For example,for patients with BCLC stage 0(very early stage) and stage A(early stage) HCC,the curable treatment modalities,including resection,transplantation and radiofrequency ablation,are taken into consideration. If the patients are in BCLC stage B(intermediate stage) and stage C(advanced stage) HCC,they may need the palliative transarterial chemoembolization and even the target medication of sorafenib. In addition,symptomatic treatment is always recommended for patients with BCLC stage D(end stage) HCC. In this review,we will attempt to summarize the historical perspective and the current developments of systemic therapies in BCLC stage B and C in HCC.展开更多
Hepatocellular cancer is the 5th most common cancer in the world and the third cause of death by malignant disease. Locoregional therapies are the most usual treatment of choice for patients with early or intermediate...Hepatocellular cancer is the 5th most common cancer in the world and the third cause of death by malignant disease. Locoregional therapies are the most usual treatment of choice for patients with early or intermediate stage of disease. The main diagnostictools for the detection of recurrence are the radiological techniques such as 4-phase computed tomography or dynamic contrast enhanced magnetic resonance imaging. However, in order to achieve best evaluation of treatment outcome and recurrence rates, there is a great need for the identification of specific and easily measured circulating biomarkers. The aim of this review is to analyze the existing data considering the prognostic significance of changes of serum diagnostic markers such as alpha-fetoprotein, des-gamma-carboxy prothrombin, alpha-fetoprotein-L3, angiogenetic factors(vascular endothelial growth factor, hypoxia inducible factor-1a) and immune parameters before and after radiofrequency ablation or transarterial chemoembolization.展开更多
文摘Hepatocellular carcinoma(HCC) is the fifth most common form of human cancer worldwide and the third most common cause of cancer-related deaths. The strategies of various treatments for HCC depend on the stage of tumor,the status of patient's performance and the reserved hepatic function. The Barcelona Clinic Liver Cancer(BCLC) staging system is currently used most for patients with HCC. For example,for patients with BCLC stage 0(very early stage) and stage A(early stage) HCC,the curable treatment modalities,including resection,transplantation and radiofrequency ablation,are taken into consideration. If the patients are in BCLC stage B(intermediate stage) and stage C(advanced stage) HCC,they may need the palliative transarterial chemoembolization and even the target medication of sorafenib. In addition,symptomatic treatment is always recommended for patients with BCLC stage D(end stage) HCC. In this review,we will attempt to summarize the historical perspective and the current developments of systemic therapies in BCLC stage B and C in HCC.
文摘Hepatocellular cancer is the 5th most common cancer in the world and the third cause of death by malignant disease. Locoregional therapies are the most usual treatment of choice for patients with early or intermediate stage of disease. The main diagnostictools for the detection of recurrence are the radiological techniques such as 4-phase computed tomography or dynamic contrast enhanced magnetic resonance imaging. However, in order to achieve best evaluation of treatment outcome and recurrence rates, there is a great need for the identification of specific and easily measured circulating biomarkers. The aim of this review is to analyze the existing data considering the prognostic significance of changes of serum diagnostic markers such as alpha-fetoprotein, des-gamma-carboxy prothrombin, alpha-fetoprotein-L3, angiogenetic factors(vascular endothelial growth factor, hypoxia inducible factor-1a) and immune parameters before and after radiofrequency ablation or transarterial chemoembolization.
